Oncocyte Stock Soars On News Of Exclusive Licensing Agreement With Burning Rock Biotech

Biotechnology company Ococyte Corporation (NYSE AMERICAN: OXC) shares are rallying premarket on Tuesday after it was announced that the company has entered into an exclusive licensing agreement with China-based Burning Rock Biotech (NASDAQ: BNR).

The deal will see the two companies bring DetermaRx, a treatment stratification test for early-stage lung cancer patients, to China.

“We believe aligning with one of the largest and fastest-growing companies in China’s NGS-based cancer therapy selection market speaks to the strength of DetermaRx as a valuable treatment stratification tool to help clarify this critical treatment decision point in early-stage tumors,” commented Ron Andrews, President and CEO of Oncocyte. 

WELCOME BONUS - Free Share Bundle When You Invest £50! Get up to £500 cashback for investing with IG.

Invest in 15,000+ shares and ETFs. Open an account now, invest at least £50, and you’ll get a free share bundle worth between £40 and £200. T&Cs apply.

5.0

Open Account Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 68% of retail investor accounts lose money when trading spread bets and CFDs with this provider. You should consider whether you understand how spread bets and CFDs work, and whether you can afford to take the high risk of losing your money.

Oncocyte will speed up the ongoing expansion of DetermaRx tests to patients and physicians outside of the US as part of the collaboration. 

Shares of Oncocyte are currently trading at $3.28, up 54.72% from the previous day’s close at $2.12. 

PEOPLE WHO READ THIS ALSO VIEWED:

• Key stock market statistics for 2020
• The best shares to buy right now
• Trade stocks with eToro